Merck & Co., Inc. Stock Euronext Paris
Equities
MRK
US58933Y1055
Pharmaceuticals
Sales 2024 * | 64.18B 59.78B | Sales 2025 * | 68.68B 63.98B | Capitalization | 331B 308B |
---|---|---|---|---|---|
Net income 2024 * | 19.51B 18.17B | Net income 2025 * | 22.25B 20.72B | EV / Sales 2024 * | 5.45 x |
Net Debt 2024 * | 18.6B 17.33B | Net Debt 2025 * | 7.28B 6.78B | EV / Sales 2025 * | 4.93 x |
P/E ratio 2024 * |
16.9
x | P/E ratio 2025 * |
14.6
x | Employees | 71,000 |
Yield 2024 * |
2.37% | Yield 2025 * |
2.5% | Free-Float | 70.77% |
Latest transcript on Merck & Co., Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
1st Jan change | Capi. | |
---|---|---|
+53.66% | 796B | |
+41.58% | 628B | |
-4.93% | 358B | |
+11.48% | 301B | |
+17.72% | 244B | |
+4.46% | 228B | |
+13.13% | 214B | |
+9.83% | 165B | |
-1.77% | 157B |